Research ArticleInflammation

The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo

See allHide authors and affiliations

Sci. Signal.  21 Feb 2017:
Vol. 10, Issue 467, eaaf8823
DOI: 10.1126/scisignal.aaf8823

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

How red berries reduce inflammation

Members of the interleukin-17 (IL-17) family of proinflammatory cytokines are important in the immune response to infections; however, excessive IL-17 signaling is associated with autoimmune inflammatory diseases, such as asthma, psoriasis, and rheumatoid arthritis. Through a screen of small molecules, Liu et al. found that cyanidin, a flavonoid found in red berries and other fruits, bound to the IL-17 receptor (IL-17RA) in a manner that blocked the binding of IL-17A. In several mouse models of inflammatory disease, cyanidin alleviated inflammation induced by T cells that produce IL-17A. Together, these data suggest that cyanidin should be further developed as a small-molecule inhibitor of IL-17A–dependent inflammatory diseases.

Abstract

Cyanidin, a key flavonoid that is present in red berries and other fruits, attenuates the development of several diseases, including asthma, diabetes, atherosclerosis, and cancer, through its anti-inflammatory effects. We investigated the molecular basis of cyanidin action. Through a structure-based search for small molecules that inhibit signaling by the proinflammatory cytokine interleukin-17A (IL-17A), we found that cyanidin specifically recognizes an IL-17A binding site in the IL-17A receptor subunit (IL-17RA) and inhibits the IL-17A/IL-17RA interaction. Experiments with mice demonstrated that cyanidin inhibited IL-17A–induced skin hyperplasia, attenuated inflammation induced by IL-17–producing T helper 17 (TH17) cells (but not that induced by TH1 or TH2 cells), and alleviated airway hyperreactivity in models of steroid-resistant and severe asthma. Our findings uncover a previously uncharacterized molecular mechanism of action of cyanidin, which may inform its further development into an effective small-molecule drug for the treatment of IL-17A–dependent inflammatory diseases and cancer.

View Full Text